Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million

Optomed Plc completed a directed share issue of 1,760,000 new shares to Finnish institutional and qualified investors, raising approximately EUR 6.0 million at a subscription price of EUR 3.40 per share (about an 11.1% discount to the 10 Dec 2025 close). Proceeds are earmarked to accelerate production, regulatory clearance and clinical trials—notably to secure FDA clearance for Optomed Lumo with integrated diabetic retinopathy AI—and to expand the company’s AI services globally as management seeks to improve sustainable cash flows. The new shares increase the company’s share count to about 21.45 million (the new shares represent ~8.9% pre-issue and ~8.2% post-issue), are expected to be registered around 12 Dec and trade on Nasdaq Helsinki around 15 Dec, and the board justified the directed placement as the fastest, most certain financing route given time, cost and execution risks of alternatives.

Analysis

Optomed completed a directed share issue of 1,760,000 new shares to Finnish institutional and qualified investors, raising gross proceeds of approximately EUR 6.0 million at a subscription price of EUR 3.40 per share, which represents an ~11.1% discount to the 10 December 2025 closing price. After registration the company expects a total share count of about 21,453,297, with the issued shares representing ~8.9% of shares and votes pre-issue and ~8.2% post-issue; registration is expected on or about 12 December and trading on Nasdaq Helsinki around 15 December.

The company launched Optomed Lumo in Q3 2025 and Lumo has received FDA PJZ classification allowing Class II marketing in the U.S., but Optomed must complete clinical trials to obtain FDA clearance to market the device with integrated diabetic retinopathy AI (e.g., AEYE Health’s algorithm). Management states proceeds will be used to ramp production, start regulatory clearance processes and expand AI services globally to improve sustainable net cash flows; the Board selected a directed placement over other capital-market alternatives citing speed, cost and execution certainty.

Implications are mixed: the financing reduces immediate liquidity risk and funds near-term commercialization activities—supporting the mildly positive market sentiment signal—while the ~11% pricing discount and ~8% dilution create short-term downside risk until clinical-trial and FDA-clearance milestones are delivered. Key execution risks remain timing of trials, regulatory outcomes and the company’s ability to convert product launch momentum into recurring revenue.

Key Decisions for Investors

• Monitor clinical-trial starts, FDA clearance progress and production ramp milestones as the primary catalysts for re-rating
• Consider adding modest exposure on meaningful weakness since the EUR 6.0m raise reduces near-term financing risk, but size positions conservatively given the 11.1% issuance discount and ~8% dilution
• Existing shareholders should consider hedging or trimming ahead of share registration/trading around 12–15 December to manage short-term dilution and volatility
• Require evidence of improving cash flow or clear commercial traction from Lumo and AI services before increasing allocation materially